A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis
- 2 January 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 23 (1), 51-57
- https://doi.org/10.1097/qad.0b013e32831c8adc
Abstract
Objective: To evaluate the efficacy of a single dose of intravenous zoledronate for the treatment of HIV-associated osteopenia and osteoporosis. Design: A double-blinded, randomized, placebo-controlled, 12-month trial of 5 mg intravenous zoledronate dose to treat 30 HIV-infected men and women with osteopenia and osteoporosis. Methods: Following zoledronate or placebo infusions, participants were followed for 12 months on daily calcium and vitamin D supplements. Lumbar spine and hip bone density was assessed at baseline, 6 and 12 months. Biomarkers of bone metabolism were measured at baseline, 2 weeks, 3, 6, 9, and 12 months. Student's t-test and repeated measure analyses were used to evaluate bone density and bone marker changes over time. Results: In the 30 HIV-infected individuals [men (27) and women (3)] in the trial, median T-scores at entry were −1.7 for the lumbar spine and −1.4 for the hip. Median CD4 cell count was 461 cells/μl, 93% had HIV-RNA viral loads less than 400 copies/ml, and 97% were taking antiretroviral medications. Bone density measured either absolutely or as sex-adjusted T-scores significantly improved in zoledronate recipients as compared with minimal changes in those receiving placebo. Bone resorption markers significantly decreased over the study period in the zoledronate recipients as compared with placebo controls. No acute infusion reactions were detected, but one patient developed uveitis, a recognized complication of zoledronate, which responded to therapy. Conclusion: In this small study, annual zoledronate appears to be a well tolerated and effective therapy for HIV-associated bone loss.This publication has 28 references indexed in Scilit:
- Reduced bone mineral density in HIV-infected patients: prevalence and associated factorsAIDS, 2008
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisThe New England Journal of Medicine, 2007
- Bone mineral density remains stable in HAART‐treated HIV‐infected men over 2 yearsClinical Endocrinology, 2007
- Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 casesInternational Journal of Oral & Maxillofacial Surgery, 2006
- Alendronate Reduces Bone Resorption in HIV-Associated Osteopenia/OsteoporosisHIV Research & Clinical Practice, 2004
- Longitudinal Evolution of Bone Mineral Density and Bone Markers in Human Immunodeficiency Virus–Infected IndividualsClinical Infectious Diseases, 2003
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityThe New England Journal of Medicine, 2002
- Strategies for Optimizing Adherence to Highly Active Antiretroviral Therapy: Lessons from Research and Clinical PracticeClinical Infectious Diseases, 2001
- Energy Intake and Physical Activity in Pima Indians: Comparison with Energy Expenditure Measured by Doubly‐Labeled WaterObesity Research, 1994
- Development of Questionnaire to Examine Relationship of Physical Activity and Diabetes in Pima IndiansDiabetes Care, 1990